The use of high-dose bolus IL-2 remains limited because of its toxicity and relatively low response rates; however, the durable responses are clinically meaningful and IL-2 has a place in recently published treatment guidelines for both melanoma and renal cancer [16-18]. This evidence concerns the gene IL2 and melanoma.